FDANews
www.fdanews.com/articles/190521-us-international-trade-commission-will-probe-south-korean-drugmaker

U.S. International Trade Commission Will Probe South Korean Drugmaker

March 11, 2019

The U.S. International Trade Commission (USITC) will open an investigation into Daewoong Pharmaceuticals’ botulinum toxin products, which are marketed under brand names like Nabota and Jeuveau.

The investigation centers around a complaint filed by Allergan and its partner Medytox, alleging that Daewoong misappropriated trade secrets to create its botox products.

Allergan and Medytox called on the USITC to issue a cease-and-desist order to the South Korean manufacturer. The case will be assigned to a commission judge who will hold an evidentiary hearing.

View today's stories